PLSE - Pulse Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
14.95
-0.22 (-1.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.17
Open15.33
Bid8.59 x 800
Ask18.30 x 800
Day's Range14.84 - 15.45
52 Week Range9.81 - 34.82
Volume51,645
Avg. Volume66,843
Market Cap252.45M
Beta1.35
PE Ratio (TTM)N/A
EPS (TTM)-2.10
Earnings DateMar 12, 2018 - Mar 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders

    Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.

  • Business Wire15 days ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 18,250 shares of Pulse Biosciences common stock to five new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 3, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire18 days ago

    Pulse Biosciences Quarterly Investor Conference Call

    Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

  • ACCESSWIRE18 days ago

    Pulse Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Pulse Biosciences, Inc. (NASDAQ: PLSE ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern Time. ...

  • Business Wire19 days ago

    Pulse Biosciences Treats Initial Patient in Its Human Study Evaluating the Effects of Nano-Pulse Stimulation in Basal Cell Carcinoma

    Pulse Biosciences, Inc. (PLSE) today announced the treatment of the first patient in a clinical study to evaluate Nano-Pulse Stimulation (NPS) in a common skin cancer, Basal Cell Carcinoma (BCC). Patients in the study will be treated with NPS prior to resection of the BCC lesion, which is the standard of care for BCC lesions. Post resection tissue samples will be assessed for elimination of the BCC lesion in the NPS treatment zone and for biomarkers indicating an immune response to the NPS-treated BCC lesions.

  • Business Wirelast month

    Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018.

  • Business Wirelast month

    Pulse Biosciences Announces Treatment of First Patients in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation for the Treatment of Sebaceous Hyperplasia Lesions

    Pulse Biosciences, Inc. (PLSE) today announced treatment of the first patients in its multicenter study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH), an unsightly benign skin lesion that typically appears on facial skin and is considered a difficult-to-treat condition with current modalities. NPS is a non-thermal technology that utilizes ultra-short, nanosecond pulsed electrical fields to directly affect cell membranes and intracellular structures while sparing non-cellular tissues.

  • Business Wire2 months ago

    Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders

    Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.

  • Business Wire2 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 30,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on June 22, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • ACCESSWIRE2 months ago

    Kaskela Law LLC Announces Investigation of Pulse Biosciences, Inc. on Behalf of Stockholders

    RADNOR, PA / ACCESSWIRE / June 20, 2018 / Kaskela Law LLC is investigating Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) on behalf of the Company's stockholders. ...

  • Business Wire3 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE) (the “Company” or “Pulse Biosciences”), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the Company’s Board of Directors (the “Board”) granted non-qualified stock options covering an aggregate of 102,000 shares of Pulse Biosciences common stock to three new employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on May 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire3 months ago

    Pulse Biosciences Quarterly Investor Conference Call

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today reported recent corporate developments and financial results for the first quarter ended March 31, 2018.

  • Business Wire4 months ago

    Pulse Biosciences to Report First Quarter 2018 Financial Results and Operational Highlights

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8, 2018.

  • Business Wire4 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employee

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 300,000 shares of Pulse Biosciences common stock to one new employee under the Pulse Biosciences 2017 ...

  • Why Alaska Air Group, Pulse Biosciences, and BJ's Restaurants Jumped Today
    Motley Fool4 months ago

    Why Alaska Air Group, Pulse Biosciences, and BJ's Restaurants Jumped Today

    Learn which companies rose on better business conditions in their industry.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Financial Select Sector SPDR Fund (NYSE: XLF ) stock ...

  • Business Wire4 months ago

    Pulse Biosciences Announces Positive Results from Its First Study Evaluating a Clinical Target at Major Scientific Meeting

    Pulse Biosciences, Inc. announced clinical efficacy results of its first multi-center study of Nano-Pulse Stimulation technology for the treatment of seborrheic keratosis lesions in humans.

  • Business Wire5 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 50,000 shares of Pulse Biosciences common stock to five new employees under the Pulse Biosciences 2017 ...

  • Business Wire5 months ago

    Pulse Biosciences Quarterly Investor Conference Call

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform today reports recent corporate developments and financial results for the fiscal quarter and year ended December 31, 2017.

  • ACCESSWIRE5 months ago

    Pulse Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 16, 2018 / Pulse Biosciences, Inc. (NASDAQ: PLSE ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 16, 2018, at 4:30 PM Eastern ...

  • Is Pulse Biosciences Inc’s (NASDAQ:PLSE) CEO Incentives Align With Yours?
    Simply Wall St.5 months ago

    Is Pulse Biosciences Inc’s (NASDAQ:PLSE) CEO Incentives Align With Yours?

    Darrin Uecker is the CEO of Pulse Biosciences Inc (NASDAQ:PLSE), which has recently grown to a market capitalization of US$266.53M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...

  • Business Wire5 months ago

    Pulse Biosciences to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

    Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report fourth quarter and full year 2017 financial results and operational highlights on Friday, March 16th, 2018.

  • ACCESSWIRE8 months ago

    Blog Exposure - Pulse Biosciences Grants Equity Inducement Awards to Its New Employees

    Stock Monitor: Lakeland Industries Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 19, 2017 / Active-Investors issued a free report on Pulse Biosciences, Inc. (NASDAQ: PLSE ), which is readily ...